PS-OCT: a promising new diagnostic tool for RPE diseases

Article

Polarisation-sensitive optical coherence tomography (PS-OCT) is a promising new tool for diagnosis, disease follow-up and the evaluation of new treatment strategies in disease affecting the retinal pigment epithelium .

Polarization-sensitive optical coherence tomography (PS-OCT) is a promising new tool for diagnosis, disease follow-up and the evaluation of new treatment strategies in disease affecting the retinal pigment epithelium (RPE), according to a study published in the February issue of the British Journal of Ophthalmology.

Stephan Michels and colleagues from the University of Vienna, the Medical University of Vienna, Austria, University Hospital Zurich, Switzerland and Moorfields Eye Hospital, London, UK evaluated pathological changes of retinal pigment epithelium using PS-OCT in 44 eyes (22 patients).

The RPE scrambles the polarization state of backscattered light (i.e. acts as a depolarizing layer), while the polarization state of transmitted light is maintained. In patients with RPE pathologies, irregularity, elevation, thickening or absence of the RPE is readily visualized by exploiting the depolarization information. Polarization scrambling in the sensory retina can be found in cases of advanced dry macular degeneration. Sclera and fibrosis show characteristic birefringence in PS-OCT.

The authors of this study believe that PS-OCT allows tissue identification based on polarization scrambling and birefringence, thus providing additional information on RPE pathologies.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.